Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.
Jpn J Clin Oncol. 2010 Apr;40(4):286-93. doi: 10.1093/jjco/hyp184. Epub 2010 Jan 19.
We studied tau and excision repair cross-complementing 1 expression to evaluate their predictive values in advanced breast carcinoma patients.
Patients treated with paclitaxel and cisplatin as the first-line chemotherapy for locally advanced or metastatic breast cancer were enrolled. The expression levels of tau and excision repair cross-complementing 1 were assessed by immunohistochemistry and examined for their associations with treatment response and survival.
Fifty-four patients were included in this study. Despite the strong association between tau expression and lower histological grade and estrogen receptor expression, tau expression remained an independent predictor for a lower response rate in multivariate analysis (odd ratio = 0.24, P = 0.02). However, tau expression was a predictor for longer overall survival in both univariate analysis (median, 57.5 vs. 30.4 months, P = 0.02) and multivariate analysis (hazard ratio = 0.36, P = 0.008). Excision repair cross-complementing 1 was not associated with treatment response or overall survival.
Tau expression but not excision repair cross-complementing 1 in advanced breast cancer predicts poor response to combination chemotherapy of paclitaxel and cisplatin. However, tau expression is significantly associated with longer overall survival.
我们研究了 tau 和切除修复交叉互补基因 1 的表达，以评估它们在晚期乳腺癌患者中的预测价值。
入组了接受紫杉醇和顺铂作为局部晚期或转移性乳腺癌一线化疗的患者。通过免疫组织化学评估 tau 和切除修复交叉互补基因 1 的表达水平，并探讨它们与治疗反应和生存的关系。
本研究共纳入 54 例患者。尽管 tau 表达与组织学分级较低和雌激素受体表达呈强相关，但在多变量分析中，tau 表达仍然是反应率较低的独立预测因素（比值比=0.24，P=0.02）。然而，tau 表达在单变量分析（中位数：57.5 与 30.4 个月，P=0.02）和多变量分析（风险比=0.36，P=0.008）中均为总生存时间的预测因素。切除修复交叉互补基因 1 与治疗反应或总生存无关。
晚期乳腺癌中 tau 表达而非切除修复交叉互补基因 1 预测紫杉醇和顺铂联合化疗的反应不良。然而，tau 表达与总生存时间显著相关。
